RxDoctor Payments Data

Matthew Edwards, MD

Family Medicine · Spartanburg, SCNPI 1700842333

Payments from drug & device makers

$1,903in general payments, 2019–2025

Across 120 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$194
  • Pfizer$181
  • Novo Nordisk$176
  • AbbVie$160
  • Lilly USA, LLC$159
  • Amgen$141
  • plus $893 from 23 others

What the payments were for

  • Food & beverage$1,81896%
  • Education$854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,903 in reported general payments places this provider in the 70th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$120,430
Medicare patients
240
Services billed
1,985

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$100,491
EliquisApixaban96$93,240
XareltoRivaroxaban27$38,931
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$31,313
MounjaroTirzepatide16$29,402
Tresiba Flextouch U-100Insulin Degludec38$24,613
JardianceEmpagliflozin13$23,040
Repatha SureclickEvolocumab16$22,833
Synjardy XrEmpagliflozin/Metformin Hcl14$17,859
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$16,799
FarxigaDapagliflozin Propanediol17$16,462
EntrestoSacubitril/Valsartan14$15,186
Breo ElliptaFluticasone/Vilanterol21$13,231
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$10,268
Invokamet XrCanagliflozin/Metformin Hcl17$7,728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$176$100,49165 claims
PfizerEliquis$181$93,24096 claims
GSKTrelegy Ellipta, Breo Ellipta$104$44,54342 claims
Boehringer IngelheimJardiance, Synjardy Xr$55$40,89927 claims
Lilly USA, LLCMounjaro$159$29,40216 claims
AstraZenecaFarxiga$102$16,46217 claims
NovartisEntresto$60$15,18614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →